Structure:
I think there are multiple paths to structure the company for success. The biggest one is to get these INDs rolling. This is the purpose of Ray Hill, a very seasoned healthcare exec... IMO
They can spin off ICBS research into a new publicly traded entity with SVFC retaining minority interest that can be dividend out to shareholders or held to eventually sell to help with debt and get the clinic, license,cryo model going. This is very plausible as it is how other biotechs have moved forward in the past..
Question is: how much would a company conducting multiple INDs using SVFC stem cell extraction and under new leadership and infused with 15 + mil be worth??? 50-100 million?? That is the rough target for some of the companies deep into INDs but using inferior enzymes, etc..
Immediate underlying value would be created for the parent..
Yesterday's close has this at about 1.5 mill.. Plenty of room for a 10-30 bagger by early next year.
About 100k in volume in 2 days after months of about 1-2k daily.. Looks to me like this is gearing up.
Good luck positioning, enjoy the weekend
